Acousia Therapeutics GmbH to share key learnings and data from its lead candidate development programs — clinical stage ACOU085 and late preclinical stage ACOU082 —
Hearing loss company Acousia Therapeutics GmbH announced the successful completion of its ACOU085 clinical Phase 1b study today, following the final visit of the last
Acousia Therapeutics GmbH, and its partners from the Translational Hearing Research Group at the Tübingen Hearing Research Center (Department of Otolaryngology, Head and Neck Surgery,
Acousia Therapeutics GmbH will be presenting data on the company’s clinical stage, first-in-class lead candidate ACOU085 at the Hanson Wade 2nd Inner Ear Therapeutics Summit
ACOU085, the lead candidate from Acousia Therapeutics, has been administered to the first patient with age-related hearing loss (presbycusis) in a Phase 1b clinical study
Acousia Therapeutics GmbH – along with its partners from the Translational Hearing Research Group at the Tübingen Hearing Research Center (Department of Otolaryngology, Head and
Acousia Therapeutics GmbH has been granted CTA (Clinical Trial Authorization) by the German BfArM (Federal Institute for Drugs and Medical Devices) for the first-in-man clinical
The senior management of Acousia Therapeutics GmbH will be discussing the company’s approach to translational development of small molecule drug candidates for the treatment of
Starting November 1, 2020, Jonas Dyhrfjeld-Johnsen will be joining the Acousia Therapeutics management team in the newly established role of chief development officer. Having worked
Acousia Therapeutics (Acousia), a leader in the discovery and development of novel therapies in inner ear-related diseases and pathologies, today announced the closing of a
